StemCell Therapy

You may not think of plants as needing life-saving medicine, but that's sometimes the case when bugs and disease strike. Now, scientists have developed a super-accurate, highly delicate way of delivering drugs, and right where plants need them.

At the moment, plants can be sprayed with pesticides, which doesn't really penetrate to the roots, or they can be treated with large needles that aren't particularly precise, and tend to cause damage to the plants.

The new method makes use of microneedles or what the researchers are calling 'phytoinjectors', sitting on top of a silk-based biomaterial patch, which are able to hit a plant's circulatory system directly. Pesticides, in contrast, might travel between the root system and the leaves.

(Cao et al., Advanced Science, 2020)

As well as delivering medicine or nutrients to different parts of the plant, the new mechanism could also be used to take samples of a plant, which are then transferred to a lab for analysis, or even to edit DNA (something the team has successfully tried).

"We wanted to solve the technical problem of how you can have a precise access to the plant vasculature," says mechanical engineer Yunteng Caofrom MIT.

"You can think about delivering micronutrients, or you can think about delivering genes, to change the gene expression of the plant or to basically engineer a plant."

The motivation for the project came from the spread of the citrus greening disease across the US and other parts of the world, which threatens to flatten an industry worth $9 billion if a solution isn't found. Olives and bananas are other fruits under particular threat from disease across the world right now.

Previous work looking at the use of microneedles to deliver human vaccines was used as a starting point, with silk kept as the basis of the material holding the microneedles.

Silk is strong, doesn't cause a reaction in plants, and can be made degradable enough to get out of the way once the drugs have been delivered.

However, a lot also had to change compared to microneedles used on humans: plants have far less water available than the human body does, so the design had to be adapted.

The team of scientists was able to boost the silk's hydrophilicity (water-attracting capabilities), and come up with a new material more suited for plants.

"We found that adaptations of a material designed for drug delivery in humans to plants was not straightforward, due to differences not only in tissue vasculature, but also in fluid composition," says biologist Eugene Lim.

Tests of the material and its microneedled payload on tomato and tobacco plants showed that it could be successful as a drug delivery system. Fluorescent molecules were used to track the progress of the injection all the way from the roots to the leaves.

The system should adapt to other plants fairly easily, the researchers say, though scaling it up is going to prove more challenging. The work should prove useful for future projects though, both in delivering life-saving drugs to save plants from disease, and in engineering them to avoid disease in the first place.

"For the future, our research interests will go beyond antibiotic delivery to genetic engineering and point-of-care diagnostics based on metabolite sampling," says environmental engineer Benedetto Marelli.

The research has been published in Advanced Science.

Visit link:
Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert

WITH food security trending across social media sites, its important to take note of the blue-sky research being carried out in Australia to future-proof our food.

While panic buying and poor logistics have caused the majority of food shortages on Australian supermarket shelves, long-term climate trends and the commercial realities of needing to 'grow more with less' have been driving researchers toward altering the way plants grow at a fundamental level.

Despite the long-winded name, the Australian National University's (ANU) Australian Research Council Centre of Excellence for Transitional Photosynthesis has a rather straightforward mission - research the ways photosynthesis can be altered to increase yield in food crops.

Centre director and ANU professor Robert Furbank said photosynthesis, the process green plants use to convert sunlight into chemical energy, could give farmers the tools to increase crop production while battling with changes to the climate.

"Australian plant scientists are punching above their weight by participating in global, interdisciplinary efforts to find ways to increase crop production," professor Furbank said.

"We essentially need to double the production of major cereals before 2050 to secure food availability for the rapidly growing world population."

Initial outcomes from the research were recently published in the Journal of Experimental Botany.

Co-editor and ANU researcher professor John Evans said the publications showed how improving photosynthesis could benefit food production.

"We are working on improving photosynthesis on different fronts, from finding crop varieties that need less water, to tweaking parts of the process in order to capture more carbon dioxide and sunlight," professor Evans said.

"We know that there is a delay of at least a decade to get these solutions to the breeders and farmers, so we need to start developing new opportunities now before we run out of options."

Professor Evans said the research covers everything from genetic engineering to synthetic biology, working across crops such as wheat, rice and sorghum.

While the pay-off from this sort of 'blue-sky' research can be decades away, professor Furbank said it was important the research was conducted now.

"It is similar to finding a virus vaccine to solve a pandemic, it doesn't happen overnight.

"We know that Australia's agriculture is going to be one area of the world that is most affected by climate extremes, so we are preparing to have a toolbox of plant innovations ready to ensure global food security in a decade or so."

Professor Furbank said this was why long-term proactive funding for blue-sky research was needed.

Read more:
Blue-sky thinking for food production - Farm Weekly

The statement by the pro-GMO expert in an article published in the Ethiopia Observer: [GMOs] in principle, [] could allow increased yield and lower production costs, which translates to increased farm income, lacks moral correctness and it is built more on theory than reality.

The author has every right to promote Genetically Modified Organisms (GMOs) but his article is one-sided, selective in its use of studies, and full of factual errors. The author who has a manifestly unbridled enthusiasm for GMOs makes some overconfident claims, starting from his opening line which says, genetically modified (GM) traits can be valuable and the discussion around them should be based on facts and in a case-by-case approach. However, he did not provide enough case-by-case examples of these traits that could be relevant to solve the problems of smallholder farmers in Ethiopia. After all, any technological intervention must be based on the needs and realities of those smallholder farmers who are the main producers of food and raw material for industrial production in Ethiopia. For instance, we have yet to see GM traits that could be effective to mitigate the devastating wheat rust, withstand extreme drought and frost, and provide a higher yield than existing crop varieties. There are numerous writings that wax lyrical about the virtues of GMOs, many of them written by paid advocates. But independent assessments on the nature and performance of GM crops in comparison with conventionally improved varieties are rare. Even if we must advocate for GMOs, it must be in consideration of the countrys interest than that of the multinationals, whose sole motive is nothing more than profit. We must also communicate facts that are relevant for smallholder farming in Ethiopia instead of stories from commercial farming in the U.S. or other industrialized countries. If the GM traits must be there, it must be with the aim to solve farmers problems.

Indeed, GMOs should not be confused with the use of biotechnology as a science. There are biotechnology tools such as marker-assisted selection that are cheaper and can be helpful in countries like Ethiopia to develop new varieties in a short period of time for use. These kinds of technologies are less risky and easy to integrate with conventional breeding in pro-poor public research institutions.

In the first paragraph, the author wrote, the genome of organisms can be altered to contain [a] genetic variants so that the GMO can express a desired trait, which could, for instance, be drought-tolerance. He adds, in principle, this could allow increased yield and lower production costs, which translates to increased farm income. The truth of the matter is, we have not yet seen super varieties or GM cultivars that have led to a huge surge in yields and tolerate moisture stress. High yield already exists in conventionally breed improved varieties. Most GMOs are created by inserting genes (e.g. from bacteria) into these high yielding varieties to produce toxins that kill insects or to become herbicide tolerant. Thus, two types of GM crops dominate todays market.

Insect-resistant GM crops these types of GM crops are developed by introducing a gene fromBacillus thuringiensis(Bt), a soil bacterium. Such GM plants or Bt-plants were created to produce toxins that kill insect pests. The advantage is that we avoid spraying synthetic chemicals to control insect-pest by growing Bt-crops. This is useful for the environment and the economy of the producer. But things get murkier when the insect evolves through time and develop resistance to Bt toxin produced by the plants. Insect resistance by GM crops breaks as much as those varieties developed through conventional breeding. Studies have already shown this problem. This would force farmers to go back to using chemicals to control the pest, making the cost of production higher as farmers would be obliged to buy expensive GM seeds as well as associated insecticidal chemicals. It also means farmers would be required to spray more chemicals, which is bad for the environment. Another problem with GM crops is that they do not have certain features compared to their counterpart conventional varieties while they maintain insect resistance. For instance, the Bt-cotton failed in Burkina Faso because the fiber quality of cotton was below standard, and farmers were forced to sell at a low price. Generally, GM crops have not demonstrated superior performance compared to conventional varieties in this regard but one thing that we could speak with certitude is they increase production costs. This is because all GMOs are patented, which makes the seeds and associated agrochemical inputs more expensive. Thus, the patent on such GM crops is an incentive for the multinationals to accumulate wealth at the expense of poor farmers.

Herbicide-tolerant GM crops these types of GM crops are modified to tolerate huge doses of chemical herbicide e.g. Roundup Ready GM soybeans. Roundup kills non-modified normal soya plants and weeds. In other words, normal soya plants and all other unwanted plants in the field (weeds) die except those GM soya plants when we spray them with Roundup. Indeed, this makes weed control easier or manageable when we have a huge soya field which otherwise is difficult to control weeds by manual weeding. This can be beneficial for large scale farmers in developed countries where labor is expensive. The problem with this type of GM crop is the emergence of superweeds as observed in recent years. These are tolerant weeds that are no longer killed by Roundup and growers must spray more of it to control weed infestation. This means it exacerbates the environmental hazard. It increases water, soil, and air pollution, which can have a devastating effect on human and ecosystem health. Still, the winners are companies who earn from the sale of a patented chemical (roundup) and GM soya seeds.

Companies are now grabbing plant genetic resources by incorporating genes from traditional plant varieties and wild relatives into GM crops through patenting.

The author correctly points out that altering the genomes of plants and animals did not begin with the emergence of genetic engineering (GE) and genetic modification in recent decades. In fact, people have been altering the genomes of plants and animals for thousands of years starting from domestication through to traditional selection and modern-day breeding, he wrote. This is why many observers find patenting plants and animals outrageous because the diversity of crops that we have today is the result of thousands of years of selection and management by farmers. Companies are now grabbing plant genetic resources by incorporating genes from traditional plant varieties and crop wild relatives into GM crops through patenting It must be underlined that companies are not inventing genes, but they are simply isolating them from farmers varieties or genetic resources in the public domain. They would go on introducing these genes to a new one to claim a patent, which gives them complete monopoly of the genes. The example of introducing a gene that confers resistance to Xanthomonas from sweet pepper to banana shows this technological practice. The same thing is being tried on Enset. This becomes unfair when the technology is monopolized by a handful of multinational companies through patents.

In my view, it is insincere to promote GMOs in a country that has weak or insufficient biosafety regulatory frameworks such as biotechnology and/or biosafety policy, laws, regulations and guidelines, administrative systems, decision-making systems and mechanisms for public engagement.

In addition to hiding these socio-economic harms from use of GMOs, the author intentionally avoids distinguishing genetic engineering from conventional breeding including the selection of better plant varieties by farmers. Genetic engineering (that involves the transfer of genes from unrelated organism to another such as between bacteria and plants to create transgenic organisms), and Genetic modification (that involves modifying the DNA of an organism by removing, replacing some genes or inserting genes from other plants of the same species) is different from farmers selection practices (conscious or unconscious). The later resulted in an enormous diversity of crops and animals we have today. This is a common communication practice by pro-GMO experts to ignore the socio-economic and ecological risks of GMOs. In my view, it is insincere to promote GMOs in a country that has weak or insufficient biosafety regulatory frameworks such as biotechnology and/or biosafety policy, laws, regulations and guidelines, administrative systems, decision-making systems and mechanisms for public engagement. While the authors doubt about Ethiopias eco-leadership is forgivable, the fact he stressed regarding earlier cultivation of GMOs in other African countries is undeniable.

I leave it to the author to learn about Ethiopias Pan-African environmental initiative by reading Dr. Melaku Woreds work and that of Dr. Tewolde Berhan Gebre Egziabher. Earlier cultivation of GMOs in other African countries is true, as the author points out. But he avoids mentioning that the use of GMOs has been restricted to few crops and countries on the continent. The U.S. and its agri-conglomerates pushed for commercial cultivation of GM crops in South Africa in the late 1990s following the countrys transition to democracy from apartheid. It is no accident, that they are trying to push for the same market opportunity in Ethiopia today. They see a similar moment in the countrys history a transition from authoritarian rule to democracy. In the last 20 years, big commercial farmers in South Africa have been growing GMOs. Egypt and Sudan have allowed GM crop cultivation, especially Bt-Cotton. Burkina Faso tried to do the same, but it largely failed. Overall, GMOs have not expanded to many African countries as hoped by the U.S and its companies in the 1990s and later years. Ethiopia, Rwanda, and Uganda seem to be the new target countries now. Uganda has allowed trials for the genetically modified banana in the last few years. Rwanda is considering opening up to genetically modified potato. GMOs have also made their way to the African Union in the form of policy through the development of the African Seed and Biotechnology Programme in 2008. But the program focuses on overall seed system development and states that GMOs can be one alternative, but it should be managed safely. I would also like to remind the author that this program was developed based on the African Model law that Ethiopia drafted in 2000, before its relaxation due to pressure from western donors and new philanthropists such as Bill and Melinda Gates Foundation. It is understandable for the author to say that GM can be a valuable tool but is no cure-all when he argues using a study done by people from Agri-food group and a study that uses data from the internet (a literature review of studies mostly done/financed by Monsanto and other companies) instead of filed level environmental and socio-economic impacts of GMOs to make conclusions. What we have been lacking is an independent study of GMOs that has no affiliation to pro- and ant-GMO movements. So, all these praises dont support the authors claims.

The author also tells that for countries with foreign currency bottlenecks like Ethiopia, reduced use of inputs such as pesticide, insecticide, and herbicide could translate to substantial foreign currency savings. Unfortunately, this is premised on flawed reasoning. Ethiopia could earn more foreign currency from exporting its organic products. Buying a technology that others benefit from will not solve its currency problem. Rather Ethiopias export will be questioned after the adoption of GMOs especially in Europe where GMOs are not welcomed both by consumers and their strict regulatory framework.

Another argument by the author is the labor-saving benefits of insect-resistant and herbicide-tolerant maize varieties. This is beside the point. It is strange to argue in this manner in a country where millions of young people are not in employment. The country might have many other problems but not labor. The author also said, GM also offers an adaptive capacity against an increasingly unpredictable future. What is proof of this? Of course, there is not. The author has simply overstretched himself. In my view, there is no risk that vulnerable smallholder farmers can bear, and Pro-GMO experts need to be honest and build public trust in Ethiopia

Image: Cotton farmers near Arba Minch, southern Ethiopia, photo Ecotextile.

This article is published under aCreative Commons Attribution-NonCommercial 4.0 International licence. Please cite Ethiopia Observer prominently and link clearly to the original article if you republish. If you have any queries, please contact us at ethiopiaobserver@protonmail.com. Check individual images for licensing details.

Continue reading here:
We need more honesty in GMO discussions - Ethiopia Observer

Having served over half her sentence, Lulu was a candidate for medical parole based on her age and health even before the coronavirus crisis. Her medical history included chronic obstructive pulmonary disease, hepatitis C, seizure disorder, and stage stage-five chronic kidney disease. She also had a heart attack and open-heart surgery in January. Release for Lulu and others in similar situations became a more urgent public health issue during the pandemic. Since early March, academic experts, medical and legal professionals, and advocates have been requesting broad release for incarcerated New Yorkersespecially the elderly, the pregnant, and those with underlying health conditions.

In jails and prisons, social distancing is impossible, and there are minimal sanitary supplies and limited medical capacity. The Release Aging People from Prison (RAPP) Campaign had called for the 9,550 people age 50 and older in state prisons be freed. As of April 30, Cuomo had released 116 older people from prisonor approximately 1 percent of the over-50 population. (He also ordered the release of up to 1,100 people in local jails on low-level parole violations.) Were Cuomo to allow the most vulnerable to go home, Donna Robinson, RAPPs Western New York regional organizer, told me, so many lives would not be lostnot only of people who are incarcerated, but the guards, the vendors, the volunteers.

As of May 1, 1,074 staff members and 375 incarcerated people at New York State prisons are confirmed positive for Covid-19; ten incarcerated people and two staff members have died. On March 30, a top doctor at New Yorks Rikers Island Jail tweeted that, in 12 days, one Covid-19 case had exploded into 200, that the virus was spreading rapidly, and that it was unlikely that the jail could stem the growth. By April 30, there were 376 cases, an infection rate of nearly 10 percent, compared to the civilian rate of 1.5 percent in the rest of the state. All numbers only reflect those who have been given tests, which are notoriously in short supply. When the Bureau of Prisons, which controls federal facilities, tested 2,700 incarcerated people for Covid-19, 71 percent of the tests came back positive.

All visitation to Bedford Hills was canceled on March 16. Incarcerated women, civilian workers, guards, and their families fell ill. Lulu wrote to Melissa on March 20, cheerful as usual, grateful for her care package of popcorn and Honey Buns. Hey Sis, How are you doing? Is the sun out up north? I got the stuff you sent me Thank you very much for all that you did Love you both and tell the kids I said hello and to continuously wash their hands and face. Love LuLu. As the virus circulated, she grew anxious. On March 28, she asked Melissa to contact people in higher places and let them know. With her underlying health issues, she added, I cannot afford to get this virus. It may kill me. Please help.

See more here:
Death of a Survivor - The New Republic

This report also researches and evaluates the impact of Covid-19 outbreak on the Animal Stem Cell Therapy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Animal Stem Cell Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Latest Market Research Report onAnimal Stem Cell Therapy Market size | Industry Segment by Applications (Veterinary Hospitals and Research Organizations), by Type (Dogs, Horses and Others), Regional Outlook, Market Demand, Latest Trends, Animal Stem Cell Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report also assesses driving forces of Animal Stem Cell Therapy market and changing dynamics which have been examined as growth-boosting factor. Also, the Animal Stem Cell Therapy study sheds light on limitations and restraints that could probably become obstruction while the Animal Stem Cell Therapy industry is proceeding to achieve substantial revenue. The report also aids readers to gain in-depth knowledge of a Animal Stem Cell Therapy market environment that comprises terms such as entry barriers, and trading policies as well as regulatory, political, financial and social concerns that may also hamper Animal Stem Cell Therapy market growth momentum.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/1189

It also facilitates clients with the acumen to gain competitive advantages in the Animal Stem Cell Therapy market and the strengths and weaknesses of their strong opponents. The Animal Stem Cell Therapy report emphasizes their strategic movements including brand expansions, public relations activities and product releases. The report highlights ideas, objectives, core business values, and niche markets of leading contributors operating in the worldwide Animal Stem Cell Therapy industry.

Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies are the main audience for Animal Stem Cell Therapy market involved in this report.

Report Scope:

Animal Stem Cell Therapy market competition by top Manufacturers:

Animal Stem Cell Therapy Market Outlook by Applications:

Animal Stem Cell Therapy Market Statistics by Types:

The study includes the profiles of key players in the Animal Stem Cell Therapy market with a significant global and/or regional presence. The study on the global Animal Stem Cell Therapy market includes qualitative factors such as drivers, restraints, and opportunities. The study covers the qualitative and quantitative analysis of the market segmented based on type, technology, and vertical. Moreover, the study provides similar information for the key geographies.

With the clear insight this report also helps in understanding Animal Stem Cell Therapy market dynamics, structure by analyzing the Animal Stem Cell Therapy market segments, and project the Animal Stem Cell Therapy market size. Actual market sizes and forecasts have been provided for all the above-mentioned segments.

The foremost points are labelled in detail which are covered in this Animal Stem Cell Therapy Market Report:

The Animal Stem Cell Therapy Analysis report offers an entire substantial study of the Animal Stem Cell Therapy market, key tactics followed by leading Animal Stem Cell Therapy industry Players and impending segments. The previous and current Animal Stem Cell Therapy industry forecast analysis in terms of volume and value along with research conclusions is a decisive part of Animal Stem Cell Therapy market analysis report.

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/1189

More:
Animal Stem Cell Therapy Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

- Company's goal to initiate clinical trial in patients in 2020

- Innovative therapy candidate uses next generation mesenchymal stem cells (MSCs) derived from a master cell bank of induced pluripotent stem cells (iPSCs)

CRANFORD, N.J., April 27, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.

The cells, called NoveCite Cells or NC-MSCs, are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. NC-MSCs are mesenchymal stem cells derived from a single donor's fibroblasts that have been dedifferentiated into an induced pluripotent stem cell (iPSC) master cell bank, thereby avoiding the need to source additional donor cells. The iPSCs are then further differentiated into a mesenchymal stem cell (MSC) therapy. Citius and Novellus plan to develop NC-MSCs for the treatment of ARDS, and last month the companies signed an exclusive option agreement.

The Company plans a multi-center randomized placebo-controlled dose-finding study followed by an expansion phase to assess the safety, tolerability, and efficacy of NC-MSCs in patients with moderate to severe ARDS due to COVID-19. The proposed trial, a Phase 1b/2 clinical trial, is titled "A Randomized Placebo-Controlled Dose-Finding Study Followed by a Dose Level Expansion to Assess the Safety and Efficacy of NoveCite MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to SARS-CoV-2 Disease (COVID-19)," or "MARCO". The primary objectives of this study are to evaluate the safety and efficacy of NoveCite cells as a treatment for subjects with moderate-to-severe ARDS due to COVID-19 and to identify therapeutic doses.

"MSCs have an established track-record of clinical safety, and have shown promise in the treatment of inflammatory lung disease," said Matt Angel, PhD, co-founder and Chief Science Officer at Novellus, Inc. "Our research has shown that the NoveCite cells, being derived from mRNA-reprogrammed iPSCs, secrete higher levels of immunomodulatory proteins than donor-derived MSCs, and have unique manufacturing advantages."

"We believe we have the key elements in place from a clinical design and manufacturing point of view to evaluate this novel cell therapy approach to deal with the current pandemic," said Myron Holubiak, Chief Executive Officer of Citius. "ARDS is a very serious complication for many patients suffering from COVID-19, and is believed to account for about 80% of the deaths in ventilated patients. There is no proven or FDA-approved treatment for it, other than oxygen therapy, including use of mechanical ventilation, and fluid management. Literature from previous investigational studies with MSCs in the treatment of lung injuries support the idea that MSCs could prove effective in treating COVID-19-related ARDS. We look forward to our FDA discussions and are excited to be at the cusp of what could be a novel and effective therapy for ARDS."

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Story continues

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 will benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Inc.Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement with Novellus within the option period; our need for substantial additional funds; the ability to access the FDA's CTAP program for the MARCO trial; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks associated with conducting trials for our product candidates, including those expected to be required for any treatment for ARDS and our Phase III trial for Mino-Lok; risks relating to the results of research and development activities; risks associated with developing our product candidates, including any licensed from Novellus, including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; uncertainties relating to preclinical and clinical testing; the early stage of products under development; risks related to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105 ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-announces-pre-ind-submission-to-fda-under-the-coronavirus-treatment-acceleration-program-for-a-novel-stem-cell-therapy-for-acute-respiratory-distress-syndrome-ards-in-covid-19-301047150.html

SOURCE Citius Pharmaceuticals, Inc.

Read this article:
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic, it is initiating staff layoffs, anticipated to affect 12 employees, primarily research and development personnel. The layoffs are expected to be completed on or around May 1, 2020. AgeX expects to pay approximately $105,000 in accrued payroll and unused paid time off and other benefits and expects to recognize approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which are expected to be settled in cash.

AgeX plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology, and PureStem cell derivation and manufacturing technology. Since the launch of its licensing and collaboration strategy in January 2020, AgeX delivered a research collaboration in Japan focused on developing universally transplantable cells for therapeutic use based on UniverCyte, and entered into a neural stem cell therapy research collaboration for neurological disorders utilizing PureStem at a California state university. AgeXs budgetary and personnel adjustments will result in the deferral of in-house work on the development of AgeX therapy product candidates, including AGEX-VASC1 and AGEX-BAT1, and its induced tissue regeneration (iTR) technology, and may also lead to outsourcing of some of that work, until further funding can be obtained to rebuild a research and development staff for one or more of those programs. Development of AgeXs iTR technology may be done at AgeXs subsidiary Reverse Bioengineering, Inc. subject to successful financing of the subsidiary.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

The rest is here:
AgeX Therapeutics Announces Reduction in Projected Cash Expenditures - Business Wire

In 2018, the market size of Canine Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Canine Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Canine Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Canine Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15550

This study presents the Canine Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Canine Stem Cell Therapy history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Canine Stem Cell Therapy market, the following companies are covered:

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15550

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Canine Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Canine Stem Cell Therapy, with price, sales, revenue and global market share of Canine Stem Cell Therapy in 2017 and 2018.

Chapter 3, the Canine Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Canine Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15550

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Canine Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Canine Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the original here:
Global Canine Stem Cell Therapy Market's Growth Trajectory Disrupted by COVID-19 Pandemic; Growth to be Restored Post Crisis Science Market Reports -...

Allosource

Stem Cell Therapy Market Competitive Landscape

In the last chapter, the analysts have studied the competitive landscape present in the Stem Cell Therapy market. The chapter also includes comments and recommendations by market experts to help the readers make the right decisions for their businesses for the forecast period. The chapter on competitive landscape presents a list of achievements made by these companies so far, mergers and acquisitions, and product innovations.

Stem Cell Therapy Market Segmentation

The extensive report on the Stem Cell Therapy market includes an executive summary that gives a brief description of the overall market, its drivers, restraints, leading segments, and competitive landscape. Each part of the executive is separately explained in the research report through dedicated chapters. The chapters are complete with precise calculations through charts and graphs.

The publication also includes individual chapters on various segments present in the market and the relevant sub-segments. Analysts have provided historical revenues and estimated revenues for all of the segments. Sales of products and the evolution of end-users have also been studied in the research report. The chapter on geographical analysis assesses the regional markets. It takes a granular view of the changing socio-political conditions, weather changes, and annual budgets of nations to determine their impact on the overall market.

We Offer up to 30% Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=NYH&utm_medium=001

Report Objectives

Analyzing the size of the Stem Cell Therapy market on the basis of value and volume.

Accurately calculating the market shares, consumption, and other vital factors of different segments of the Stem Cell Therapy market.

Exploring the key dynamics of the Stem Cell Therapy market.

Highlighting important trends of the Stem Cell Therapy market in terms of production, revenue, and sales.

Deeply profiling top players of the Stem Cell Therapy market and showing how they compete in the industry.

Studying manufacturing processes and costs, product pricing, and various trends related to them.

Showing the performance of different regions and countries in the Stem Cell Therapy market.

Forecasting the market size and share of all segments, regions, and the global market.

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=NYH&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

Our Trending Reports

Metabolomics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
Stem Cell Therapy Market Growth Opportunities, Key Companies, Outlook, Drivers and Forecast to 2026 - New York Headlines USA

An Indian American professor has developed the technology behind the Nanolife Disinfectant Tunnel, which successfully uses silver nano-particles to kill off viral infections.

Kattesh Katti, professor of radiology and director of the Institute of Green Nanotechnology at the University of Missouri in Columbia, Mo., told India-West the technology has been tested successfully on COVID-related viruses. Currently, the 8-foot-long tunnel has been deployed at three locations in Chennai, including the Tirumala Tirupati Temple, where thousands of devotees worship each day.

Indias Prime Minister Narendra Modi has placed an order for more tunnels, according to Katti, which are distributed in India through the company Nanolife.

Katti discovered the effectiveness of silver nano-particles in killing off viruses 20 years ago, and commercialized the technology via a hand sanitizer that uses no alcohol or chemicals. The technology was also being used as a cleaning agent in Indian hospitals, he said.

Then the COVID-19 pandemic hit; Katti and the team at Nanolife re-purposed their technology to address the global crisis, which has killed more than 214,000 people around the world, and infected more than three million people.

India, currently on a nationwide quarantine ordered by Modi in March, has a relatively low rate of infection and death from COVID-19: the country had reported 937 deaths and approximately 30,000 infections as of April 28.

But the countrys overcrowded conditions which make required social distancing difficult could drastically raise the number of deaths from the virus, predict Indian epidemiologists.

A country like India really needs more resources, Katti told India-West. The very high population density makes the pandemic significantly more dangerous, he said.

Unlike other disinfecting tunnels currently used in India and some other countries, Nanolifes disinfectant tunnel uses no harmful chemicals, which could be toxic. The technology is based simply on silver nano-particles, water and a proprietary herb that keeps the particles intact, said Katti, adding that the product is used in very low concentrations in the tunnels.

Prof. Jagat Ram of the Postgraduate Institute of Medical Education and Research, Chandigarh, and Prof. JS Thakur, chairman, Covid-19 Prevention Committee at PGI, have questioned the efficacy of disinfecting tunnels, stating that they provide people with a false sense of security. But the tunnels to which they were referring to use sodium hypochlorite, which is known to have several serious side effects. Nanolifes tunnels have no side effects, according to Katti.

The Government of India has banned the export of COVID-related technology, citing the huge need within the country for such products. Thus, for the moment, the Nanolife Disinfectant Tunnel is limited to deployment in India, but Katti is aiming to eventually bring the device to the U.S.

The Dharwad native said he envisions the Nanolife Disinfectant Tunnel in front of railway stations, airports, office buildings, and other large gathering places. Demand far outweighs production capability at the moment, he told India-West.

According to his bio, green nanotechnology is at the focal point of Katti's approach to pursuing research in nanotechnology and molecular medicine as he strongly believes in the total elimination of toxic chemicals in the production of engineered nanoparticles.

He uses phytochemicals occurring naturally within plants and herbs for nano constructs in a variety of applications.

Originally posted here:
Missouri Indian American Professor Develops Disinfecting Tunnel to Kill Viral Infections Using Silver Nano-particles - India West

Apr 29, 2020 06:57 PM EDT

Researchers have made new inroads into understanding aerosol treatments for asthma to help in improvements of the drug in the future. Such innovation can potentially help asthma patients.

Asthma is a disease of the lungs that affects around 330 million people all over the world. It is a major worldwide health concern. Presently, the best treatment form and preparation available with the most beneficial impact are aerosols inhaled directly into the patient's lungs. It is a challenge for researchers because our current knowledge regarding the microstructure of drugs before being converted to aerosol is quite limited.

Such aerosol preparations arecarrier-based DPI or dry powder inhalers, which must be characterized accurately for particle size distribution, surface roughness, flow properties, and fines contents. It is critical to understand the powder formulation's micro-structure, but before the current research, characterization techniques have not given complete information.

Conventional techniques include optical microscopy or OM and laser diffraction or LD. These techniques are limited because the particles are assumed to be spherical and because they provide varying results based on particle dispersion and orientation.

Scientists from theUniversity of Manchesterhave done research that sheds light on this aspect. Using X-Ray Micro-Computer Tomography (or XCT) scanning, the microstructure of the drug's particles have been quantified to the nano-level or scale.

Researchers revealed this 3D microstructure for the first time. It gives the scientific community, medical researchers, and pharmaceutical companies more understanding regarding the drug's behavior when it is aerosolized.

Dr. Parmesh Gajjar, the research's lead author, said that the team was successful in visualizing a 3-D drug-blend to see the interaction between its active ingredient and its non-drug particles. Such insight is essential in the final step of quality control of drug production. It will enable producers to verify the actual drug content in the medicine and help in coming up with better formulations, and thus improve its effectiveness.

The XCT equipment and instruments that the research team utilized is located at the world-leading HMXIF or the Henry Moseley X-ray Imaging Facility. This facility is housed at the University of Manchester. The facility and equipment are capable of analyzing samples at a resolution as small as 50nm.

The research is very important in obtaining knowledge about asthma inhalation medicines, which need aerosolization for generating particles small enough to be absorbable by the lungs. The project studied particles that are tiny enough to be able to reach into the lung's deepest recesses.

The research's novel technological innovation was one of the papers proposed to be presented at the2020 Respiratory Drug Delivery conference(RDD); it was chosen one of the key presentations at the said global conference. The venue of the conference was initially booked at Palm Springs. Still, due to the coronavirus pandemic and the lockdowns it caused, the organizers first opted to make it an online event instead and has currently been canceled until further notice.

The study was published in theEuropean Journal of Pharmaceutics & Biopharmaceuticsand is entitled "3D Characterisation of Dry Powder Inhaler Formulations: Developing X-Ray Micro Computed Tomography Approaches.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

See the original post:
New Insights in Asthma Medicines May Improve Future Drugs and Treatment - Nature World News

Global Regenerative Medicine Market Added by Report Ocean covers valuable insights based on market valuation, market size, SWOT Analysis, revenue forecast and regional outlook of this industry. The research also presents a precise summary of the industry competitive spectrum, while drawing attention to the growth prospects and expansion plans adopted by key market players.

The global regenerative medicine market report is a comprehensive research study of this business space that has been projected to garner highly appreciable returns by the end of the forecast duration. The report analyzes global regenerative medicine market and provides an insight into pivotal parameters such as market size, sales volume, revenue forecast. The segmentation of the global regenerative medicine market and intrinsic details regarding these segments in addition to the specific drivers fueling the remuneration and commercialization landscape of this business space have also been enumerated in this report.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=43390

In this report, we analyze the Global Regenerative Medicine Market from two aspects.

1. Production In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019.

2. Consumption In terms of consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019.

We also make a prediction of its production and consumption in coming 2020-2026.

At the same time, we classify different regenerative medicine market based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. It also focuses on market influencing factors, competitive landscape, data, trends, information, and exclusive vital statistics of the market.

A brief summary of how the regenerative medicine market will perform has been illustrated in the report. Moreover, crucial specifics such as growth drivers as well as the expected growth rate of the regenerative medicine market during the forecast period are included in the report. The report also details the potential growth aspects along with the restraints of this industry vertical.

Global Regenerative Medicine Market report focuses on various key parameters that include:

Market concentration ratio

Consumption growth rate

Growth rate

Turnover predictions

Industry drivers and major challenges

Recent market trends

Geographical segmentation

Competitive structure

Competitive ranking analysis

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the regenerative medicine market report; it identifies direct or indirect competitors in the market.

Key parameters which define the competitive landscape of the Global Regenerative Medicine Market:

Profit margins

Product sales

Company profile

Product pricing models

Sales geographies

Distribution channels

Industry evaluation for the market contenders

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of regenerative medicine market. The common characters are also being considered for segmentation such as global market share, common interests, worldwide demand and supply of Access Control devices. Moreover, the report compares the production value and growth rate of regenerative medicine market across different geographies.

Unravelling the geographical landscape of the Global Regenerative Medicine Market:

Americas (United States, Canada, Mexico, Brazil)

APAC (China, Japan, Korea, Southeast Asia, India, Australia)

Europe (Germany, France, UK, Italy, Russia, Spain)

Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

The research methodology adopted by analysts to study the market include inputs derived from industry professionals across the value chain and various other secondary research methods, along with primary research as a major tool for market study.

Some of the Major Highlights of TOC covers:

Executive Summary

Global Regenerative Medicine Market Insights

Global Regenerative Medicine Market forecast by different Segments and Regions

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of regenerative medicine market

Key Figures of Major Manufacturers

Development Trend of Analysis of regenerative medicine market

Global Regenerative Medicine Market Trend Analysis

Global Regenerative Medicine Market Size (Volume and Value) Forecast 2020-2026

Marketing Channel

Direct Marketing

Indirect Marketing

Global Regenerative Medicine Market Customers

Market Dynamics

Market Trends

Opportunities

Market Drivers

Challenges

Influence Factors

Methodology/Research Approach

Research Programs/Design

Market Size Estimation

Market Breakdown and Data Triangulation

Data Source

Key Questions Addressed in the Report:

1. Who are the top 10 players operating in the regenerative medicine market?

2. What are the driving factors, restraints, opportunities, and challenges in the regenerative medicine market?

3. What are the current scenario and industry trends in the regenerative medicine market?

4. Which industry and technology can be a potential revenue pocket for market players in the next five years?

5. Who are the visionary leaders, dynamic differentiators, innovators, and emerging players and what are the key strategies adopted by them to strengthen their positions?

6. What are the regenerative medicine market opportunities and threats faced by the vendors in the regenerative medicine market?

7. What are the regenerative medicine market challenges to market growth?

8. Analysis based on historical information along with the current trends to estimate the future of the market

9. Analysis of the impact of constantly changing global market scenarios

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=43390

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or country-based analysis can be provided as a part of customization

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Nick MartinEmail:[emailprotected]

Read this article:
Global Regenerative Medicine Market Industry Analysis and Forecast (2019-2026) by Product type, Application and Region Cole Reports - Cole of Duty

The global Regenerative Medicine market offers a thorough study of all the important aspects of the market. All the factors that are responsible for the growth of the global market are studied in this report. In addition to that, the factors causing hurdles in the path are also studied in the report. For the study of any market it is very important to study some factors such as market trends, revenue growth patterns market shares, demand and supply. In addition, it also covers political and social factors which is likely to affect the growth of the market. Production, market share, revenue rate, key regions and major vendors are some of the vital aspects analysed in the report. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users.

Get sample copy of Regenerative Medicine Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/52

The global Regenerative Medicine market is a detailed research report which covers all the quantitative as well as qualitative aspects about the Regenerative Medicine markets across the globe. The report is also inclusive of different market segmentation, business models and market forecasts. This market analysis enables the manufacturers with impending market trends. A thorough scrutiny of prominent market players or industrialists are vital aspect for planning a business in the market. Also, study about the rivals enables in attaining valuable data about the strategies, companys models for business, revenue growth as well as statistics for the individuals attracted towards the market. This report is very useful for the new entrants as it offers them with the idea about the different approaches towards the market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analysed in the report includes market share, production, key regions, revenue rate as well as key players. This Regenerative Medicine market report also provides the readers with detailed figures at which the Regenerative Medicine market was valued in the historical year and its expected growth in upcoming years. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users. In addition, the report include deep dive analysis of the market, which is one of the most important features of the market.

In addition, the market research industry delivers the detailed analysis of the global Regenerative Medicine market for the estimated forecast period. The market research study delivers deep insights about the different market segments based on the end-use, types and geography. One of the most crucial feature of any report is its geographical segmentation of the market that consists of all the key regions. This section majorly focuses over several developments taking place in the region including substantial development and how are these developments affecting the market. Regional analysis provides a thorough knowledge about the opportunities in business, market status & forecast, possibility of generating revenue, regional market by different end users as well as types and future forecast of upcoming years.

The company profiles also covers the detailed description and segmentation of the companies along the finances which are being covered for the company. The global Regenerative Medicine market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market. Furthermore, several factors such as the emergence of new opportunities is also likely to boost the growth of the market. In addition, the market research provides several detailed analysis for the market which has an impact for the end user.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

View original post here:
Regenerative Medicine Market Analysis by Demand, Applications, End Users, Companies, Sales Prospects, Forthcoming Developments, Business Opportunities...

Dr. Timothy Chan, an immuno-oncology and cancer genomics expert, has been named director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic, according to a news release.

He will lead the new center, which brings together multidisciplinary experts from across the system to advance research and treatment related to immuno-oncology, a rapidly growing field.

"Immunotherapy is the future of research in cancer and various other diseases and Cleveland Clinic has made it a priority by establishing this new center," Dr. Serpil Erzurum, chair of the Clinic's Lerner Research Institute, said in a prepared statement. "The Center for Immunotherapy and Precision Immuno-Oncology will empower clinicians and scientists throughout the enterprise to advance personalized cancer care and breakthrough immunotherapy research at Cleveland Clinic."

The center, which opened this month with the arrival of Chan, was approved in 2019.

Chan joins the system from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he led the Immunogenomics and Precision Oncology Platform and was a tenured professor, the PaineWebber Chair and the Translational Oncology Division chair, according to the release, which notes he is a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University and is on staff in the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute, according to the release.

The Center for Immunotherapy and Precision Immuno-Oncology will have four arms: a Cleveland cell therapy program in collaboration with the Case Comprehensive Cancer Center; immunologic medicine and immuno-oncology labs; a precision immuno-oncology program; and a precision immuno-oncology and developmental therapeutics program.

The center will recruit experts from around the country and globe who specialize in computational science, immunotherapy and cancer immunology, according to the release.

Initially, the new center will have sites focused on immunotherapy research and developmental therapeutics in both Cleveland and the Cleveland Clinic Florida Research and Innovation Center, a 107,000-square-foot laboratory and office space slated to open this summer in Port St. Lucie, Fla. Chan will also collaborate with experts in the new Center for Global and Emerging Pathogens, which was announced last week after a year and a half of planning. This center looks to broaden the understanding of emerging pathogens (from Zika virus to SARS-CoV-2, which causes COVID-19) and expedite critically needed treatments and vaccines.

"Innovation in precision immunotherapy is one of the most exciting areas in cancer research," said Dr. Brian Bolwell, chairman of Taussig Cancer Institute, Cleveland Clinic Cancer Center, in a prepared statement. "The addition of Dr. Chan, a pioneer in cancer genomics, and the new center's focus on research and clinical trials will strengthen our ability to provide advanced treatment options for our patients."

Board certified in radiation oncology and an elected member of the Association of American Physicians, Chan earned his M.D. and Ph.D. in genetics from Johns Hopkins University, where he completed his residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology, according to the release. He has published more than 200 articles in peer-reviewed journals, has made landmark discoveries in his field and has received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018, according to the release.

Read more:
Dr. Timothy Chan to lead Cleveland Clinic's new Center for Immunotherapy and Precision Immuno-Oncology - Crain's Cleveland Business

Recently, the Federal service for supervision in the sphere of health issued the first Russian license for the production of biomedical cell products. She became the owner of a domestic biotechnology company Generium. This will make a significant breakthrough in the field of regenerative medicine.Regenerative medicine is one of the most rapidly growing industries. Its main task is to replace and restore the function of diseased organs or tissues in cases when the natural regenerative capacity of the organism is not able to ensure the restoration and healing of the defect.Methods of regenerative medicine directed on treatment of severe socially significant diseases with high levels of disability, as well as to fill therapeutic niches with high unmet needs.Cellular technology is the most advanced tool of personalized medicine. The presence of a unique infrastructure of Russian biotechnological enterprises making them the center of attraction for the representatives of international pharmaceutical industry and scientists from various fields of science (medics, biologists, physicists, engineers, chemists, IT specialists, mathematicians), and also allows to solve the most challenging public tasks in the field of health. Industrial tissue engineering becomes a reality, said the first Deputy Minister of industry and trade of the Russian Federation Sergey Tsyb.The main segments of the market for regenerative medicine products are tissue therapy and cell therapy biomedical cellular products, which is a cultured human cells. These lines are a driver in research activities of Russian and foreign research centers, which brings together scientists and clinicians around the world.Under the current license it is planned to develop and produce a unique range of autologous, allogeneic and combined BMK, and personalized therapy and diagnostics. Regenerative medicine is not a new technology in medicine and the other medicine. Developing methods for the modification of the cells and edit their genome. There is the prospect of a new therapy, which will focus not only on the regulation of living cells, but also to grow new cells, tissues, structures in our body. With the advent of the first industrial license we understand that regenerative medicine has the potential to become a new efficient branch of the Russian medicine for the treatment of the most severe human diseases incurable by other means, concluded the Dean of the faculty of fundamental medicine of Moscow state University. Lomonosov, academician of RAS AllLod Tkachuk.The world of biotechnology in the field of regenerative medicine are at the stage of explosive growth and investment. A persons ability to manage intra and extracellular processes helps us to create technologies to solve the most difficult tasks in the treatment of patients with serious illnesses or injuries. The countrys first license for industrial production of biomedical cell products gives Russia the opportunity to implement a number of sophisticated cutting edge projects, including to combat coronavirus infection. The country began the era of cellular technologies, said Professor, General Director of JSC GENERIUM Dmitry Kudlay.

More:
Breakthrough in regenerative medicine. Biomedical cell products in Russia - The KXAN 36 News

Like power lines in an electrical grid, long wiry projections that grow outward from neurons -- structures known as axons -- form interconnected communication networks that run from the brain to all parts of the body. But unlike an outage in a power line, which can be fixed, a break in an axon is permanent. Each year thousands of patients confront this reality, facing life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed.

New research by scientists at the Lewis Katz School of Medicine Temple University (LKSOM) shows, however, that gains in functional recovery from these injuries may be possible, thanks to a molecule known as Lin28, which regulates cell growth. In a study published online in the journal Molecular Therapy, the Temple researchers describe the ability of Lin28 -- when expressed above its usual levels -- to fuel axon regrowth in mice with spinal cord injury or optic nerve injury, enabling repair of the body's communication grid.

"Our findings show that Lin28 is a major regulator of axon regeneration and a promising therapeutic target for central nervous system injuries," explained Shuxin Li, MD, PhD, Professor of Anatomy and Cell Biology and in the Shriners Hospitals Pediatric Research Center at the Lewis Katz School of Medicine at Temple University and senior investigator on the new study. The research is the first to demonstrate the regenerative ability of Lin28 upregulation in the injured spinal cord of animals.

"We became interested in Lin28 as a target for neuron regeneration because it acts as a gatekeeper of stem cell activity," said Dr. Li. "It controls the switch that maintains stem cells or allows them to differentiate and potentially contribute to activities such as axon regeneration."

To explore the effects of Lin28 on axon regrowth, Dr. Li and colleagues developed a mouse model in which animals expressed extra Lin28 in some of their tissues. When full-grown, the animals were divided into groups that sustained spinal cord injury or injury to the optic nerve tracts that connect to the retina in the eye.

Another set of adult mice, with normal Lin28 expression and similar injuries, were given injections of a viral vector (a type of carrier) for Lin28 to examine the molecule's direct effects on tissue repair.

Extra Lin28 stimulated long-distance axon regeneration in all instances, though the most dramatic effects were observed following post-injury injection of Lin28. In mice with spinal cord injury, Lin28 injection resulted in the growth of axons to more than three millimeters beyond the area of axon damage, while in animals with optic nerve injury, axons regrew the entire length of the optic nerve tract. Evaluation of walking and sensory abilities after Lin28 treatment revealed significant improvements in coordination and sensation.

"We observed a lot of axon regrowth, which could be very significant clinically, since there currently are no regenerative treatments for spinal cord injury or optic nerve injury," Dr. Li explained.

One of his goals in the near-term is to identify a safe and effective means of getting Lin28 to injured tissues in human patients. To do so, his team of researchers will need to develop a vector, or carrier system for Lin28, that can be injected systemically and then hone in on injured axons to deliver the therapy directly to multiple populations of damaged neurons.

Dr. Li further wants to decipher the molecular details of the Lin28 signaling pathway. "Lin28 associates closely with other growth signaling molecules, and we suspect it uses multiple pathways to regulate cell growth," he explained. These other molecules could potentially be packaged along with Lin28 to aid neuron repair.

Reference:

Fatima M. Nathan, Yosuke Ohtake, Shuo Wang, Xinpei Jiang, Armin Sami, Hua Guo, Feng-Quan Zhou, Shuxin Li. Upregulating Lin28a Promotes Axon Regeneration in Adult Mice with Optic Nerve and Spinal Cord Injury. Molecular Therapy, 2020; DOI: 10.1016/j.ymthe.2020.04.010

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
Scientists Regenerate Neurons in Mice with Spinal Cord Injury and Optic Nerve Damage - Technology Networks

Its still not clear whether Gov. Kate Brown will allow some beauty treatments to resume as part of her decision to allow medical offices to restart elective procedures as early as Friday after more than a monthlong shutdown to stem the spread of the novel coronavirus.

After several days of questioning from The Oregonian/OregonLive, the governors office said Brown didnt intend to allow aesthetician services, medical spas, facial spas, and non-medical massage services to reopen.

But how about doctors or nurse practitioners who provide medical beauty services such as wrinkle reduction?

Spokeswoman Liz Merah said to stay tuned. The state might have additional guidance on opening day, she said.

In a sampling by The Oregonian/OregonLive, some owners believed they werent allowed to reopen, while others were adamant that the governor had given their industry permission to restart anti-aging or aesthetic procedures meant to improve the appearance of the skin or body.

Neighboring governors also have announced the loosening of some restrictions on the medical industry, albeit on a more limited basis than in Oregon.

California Gov. Gavin Newsom said last week that some elective or delayed surgeries -- such as those for cancer or heart problems -- can resume. But Newsom specified cosmetic surgeries are still barred for the time being.

Washingtons Gov. Jay Inslee on Wednesday clarified a previous order restricting nonurgent procedures. He gave health care providers more leeway to resume some of the procedures if delaying them would significantly harm the patient. Inslees direction appears to offer no wiggle room for Botox businesses or other medical spas to reopen.

The confusion in Oregon arose when Brown announced last week that elective, non-urgent medical and dental procedures could restart but didnt offer a specific list of businesses.

She and Dr. Dana Hargunani, the Oregon Health Authoritys chief medical officer, cited examples instead -- including knee surgeries, fertility treatments, dental cleanings, cancer biopsies and hip replacements.

When a reporter asked Hargunani whether cosmetic procedures would be allowed, Hargunani didnt answer directly yes or no. Instead, she left the door open, saying: We are not telling providers exactly what they can or cannot do. But we know that those that are most urgent and necessary are going to be the first on the list.

That might have looked like a green light to many.

Aesthetic Medicine run by Dr. Jerry Darm -- one of the most recognizable faces in Oregons medical beauty industry -- announced his Lake Oswego office will start seeing customers again Monday.

We are reopening May 4th!!!!! Darms Facebook page reads. We are so excited to see our patients and have our staff back. There will be new guidelines for scheduling an appointment but we are feeling very blessed.

The post was met with a flurry of likes and comments such as Awesome!!!! I can wait to see you again and Thats so good to hear the good news.

Darm and the operators of several other medical beauty businesses contacted by the newsroom didnt return messages asking for details about safety protocols and the reason for their decisions to reopen. That includes Key Laser Institute for Cosmetic Regenerative Medicine in outer Southwest Portland, which posted on its Facebook page that its gearing up to see patients again.

Key Laser Institute for Cosmetic Regenerative Medicine's Facebook Post April 27, 2020. (Facebook screenshot)

Some others said its far too soon. Theyre concerned that meager testing means the state doesnt have a handle on the true scope of the problem or the knowledge needed to contain the virus spread through contact tracing.

While Oregon has by far a lower number of known cases and deaths than some other states -- 2,510 positive tests and 103 deaths it also has tested only about one in every 100 residents.

Coronavirus in Oregon: Latest news | Live map tracker |Text alerts | Newsletter

Debora Masten, a certified advanced esthetician in Salem, said she wont start offering customers chemical peels, laser hair removals and other treatments Friday because she doesnt think her services are necessary at this stage in the pandemic.

Its supposed to be stuff you cant put off, Masten said. Im anxious to get open again, too, but I think we have to try as best we can to protect the public.

Masten also noted that like many others who perform a range of treatments, shes not a doctor or nurse practitioner and the governor hasnt given her the OK. Thats even though she sees others who also arent medical professionals gearing up to reopen.

Sharon Griffin, a naturopathic doctor who operates Plush Botox Bar in Northeast Portland, wrote the governor this week urging her to end the confusion.

She asked Brown to specifically require the medical beauty industry to remain shuttered, like so many other businesses ranging from clothing stores to hair salons to dine-in restaurants.

No one really needs Botox in May, but as things stand, theyre gonna get it and possibly a whole lot more in the bargain, Griffin wrote.

She said in an interview that she supports restarting necessary procedures, like her husbands CT scan scheduled next week to diagnose a medical problem.

But she has decided to hold off reopening her own business until at least June 1 to see how the spread of the disease continues to play out, even as she sees competitors around her planning to reopen.

Griffin said shes passionate about what she does -- injectables such as Botox and lip fillers -- but doesnt want to risk the health of customers for procedures that arent life or death matters.

Nobody will die from a wrinkle, Griffin said.

-- Aimee Green; agreen@oregonian.com; @o_aimee

Subscribe to Oregonian/OregonLive newsletters and podcasts for the latest news and top stories.

Read this article:
Confusion reigns over whether Oregonians can receive Botox, other beauty treatments during the coronavirus pa - OregonLive

Last week, we published a briefing that flip-flopped between bad news and good(ish) news. Were balancing todays briefing in a similar vein, tempering the more negative with the more hopeful.

Todays Coronavirus Briefing is 1,078 words and will take you five minutes to read.Click here to sign up for the newsletter.

Bad. Good. Hopeful. Scary. Thank you. Very sad.

Sponsored content

With the COVID-19 outbreak causing an unprecedented impact on the Healthcare Marketing Industry, non-personal promotion has never been more critical. As HCPs are facing this crisis on both professional personal fronts, supporting them through the delivery of your key messaging will be important to the continued care of patients with existing illnesses and chronic conditions.

This is all good, and aspirational news.

Fingers crossed we get to report positively about all of the above, in the coming weeks.

A range of views of our various futures: revolutionary, hopeful, dark and progressive.

A Magic 8-Ball seems like as plausible a barometer for whats to come as anything, or anyone else these days.

Lately, for every Instagram post of someones elaborate meal is an outdoor post of their new-found gardening skills.

If the virus returns this winter, were all going to have to learn vertical indoor farming.

A brief rabbit hole of workplace nostalgia.

See you tomorrow in shoulder pads and feathered hair in quarantine no ones around to see...

Follow this link:
Coronavirus Briefing: Medical breakthroughs, the future of PR, gardens and workplace nostalgia - PRWeek

SAN DIEGO, May 1, 2020 /PRNewswire/ --SunevaMedical,Inc., is proud to announce an exciting new partnership that will further its leadership position in regenerative aesthetics. The exclusive North American distributorship for Sinclair Pharma's innovative Silhouette Instalift sutures will expand Suneva Medical's aesthetic portfolio that addresses the growing market demand for natural and minimally invasive alternatives in aesthetics.

"We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio," saysPat Altavilla, CEO, Suneva Medical. "These unique sutures fit perfectly as they can provide immediate lift to sagging cheeks and, like Bellafill, can activate the patient's natural collagen production over time."

"With Suneva Medical, we have a partnership with a company that has strong commercial presence in the U.S. while giving us the ability to expand our footprint in the North American market," says Chris Spooner, CEO Sinclair Pharma.

To learn more about Suneva Medical and upcoming news from the aesthetics company, please visitwww.SunevaMedical.com.

About Suneva Medical, Inc.Suneva Medical, Inc.headquartered inSan Diego, CAis a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva Medical offers a portfolio of best-in-class products that include Bellafill, the only FDA approved 5-year filler, Puregraft, a unique fat grafting system and Amplifine, an innovative high density platelet rich plasma (PRP) get tube.For more information, visitwww.sunevamedical.com.

About Sinclair PharmaSinclair Pharma is a fully owned subsidiary of Huadong Medicine Limited and headquartered in London, UK. The company operates in the fast growth, global aesthetics market and has built a strong portfolio of differentiated, complementary aesthetics technologies, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Group has an established sales and marketing presence in the leading EU markets, Brazil, Mexico, UAE and South Korea and a network of international distributors. For more information, visit http://www.sinclairpharma.com.

More:
Suneva Medical Increases Its Leadership in Regenerative Aesthetics with New Partnership - WFMZ Allentown

Mercy Plastic Surgery

1229 E. Seminole Suite 340, Springfield, MO |417-820-9330Theres a new member of the team at Mercy Plastic Surgery! Dr. Raghu Nandan is new to Springfield, but not to the operating room. Dr. Nandan is Board Eligible since completing his plastic surgery training at Johns Hopkins University in Baltimore after general surgery with the University of Arizona. Mercy was glad to welcome him in August of 2019.

Dr. Nandan offers head-to-toe care for his patients in Mercys high-quality medical facilitieshe specializes in breast reconstructions and augmentations, cosmetic injections, complex facial plastic surgery, scar revisions, tummy tucks and liposuction. He also assists in the care of breast cancer and melanoma patients.

When asked what he loves most about his work, Dr. Nandan says that he enjoys the opportunity to spend time with his patients, listening to their needs. He believes that by listening to patients, he can connect with them to better understand the best way to help them get the outcome they are looking for. Making positive changes in peoples lives, restoring their form and function and improving their quality of life gives him joy the fact that they can feel more confident is the best part of his career.

Tell us about a time you improved someones life, how you did it and how it felt.I had a teenage patient that was preparing for a leg amputation. Instead, we were able to restore the form and function of his leg. He later walked into the clinic and was showing off his soccer skills to the staff. Being a part of his care was priceless.

Why did you choose to go into your current profession?I chose to be a plastic surgeon to be able to restore form, function and aesthetics, from head to toe. It is one of the very few fields of medicine where you are able to innovate, push the envelope and markedly improve the quality of life and confidence of your patients.

Continue reading here:
Health These Springfield Experts Want to Help You Be Your Best Self When do you feel - 417mag